Genomic profiling of prostate cancer patients has identified a broad range of Wnt signaling components that are genetically altered (predominantly APC and CTNNB1) and highlighted Wnt pathway components as actionable therapeutic targets that may also harbor predictive value for metastatic disease. This evidence concerns the gene CTNNB1 and Familial prostate cancer.